[64Cu]Cu-AKY-2519 in Metastatic castration-resistant prostate cancer: NCT07581184 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 15 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1
Clinical phase
Recruiting
Recruitment status
not reported
Planned enrollment
2027-12-01
Primary-completion proxy
Executive view
NCT07581184 evaluates [64Cu]Cu-AKY-2519 in Metastatic castration-resistant prostate cancer. The disclosed sponsor is Aktis Oncology, Inc., the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Occurrence of adverse events by severity and occurrence of serious adverse events (SAEs) in participants who received [225Ac]Ac-AKY-2519, assessed over Up to 30 days following last administration of [225Ac]Ac-AKY-2519.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07581184 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Metastatic castration-resistant prostate cancer landscape. Drug & Asset MCP drug_fetch was queried for [64Cu]Cu-AKY-2519, while Company & Deal Intelligence MCP organization_fetch was queried for Aktis Oncology, Inc..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07581184 | [64Cu]Cu-AKY-2519 | Phase 1 / Recruiting | Aktis Oncology, Inc. | United States | Occurrence of adverse events by severity and occurrence of serious adverse events (SAEs) in participants who received [… Up to 30 days following last administration of [225Ac]Ac-AKY-2519 | 2027-12-01 |
| NCT07621692 | [161Tb]Tb PSMA I&Tc | Phase 1 / Recruiting | National Taiwan University Hospital | Taiwan Province | Treatment-emergent adverse events From enrollment to the end of post-treatment surveillance, at least 3… | 2030-12-31 |
| NCT07607990 | Indomethacin | Not Applicable / Recruiting | Zhejiang University | China | The incidence of moderate to severe CRBD within 0-1 hour after surgery The postoperative time was calculated from the moment the patient was… | 2026-12-31 |
| NCT07608848 | [177Lu]Lu-DOTA-STR-17126 | Early Phase 1 / Recruiting | Integrated Clinical Oncology Network Pty Ltd. | Australia | Number of participants with adverse events (AEs), serious adverse events (SAEs), with abnormal laboratory parameters (h… Day 43 | 2028-05-30 |
| NCT07598032 | Calcium carbonate/Vitamin D | Phase 3 / Not yet recruiting | Sponsor not reported | Nigeria | Proportion of Men with Advanced Prostate Cancer with Vitamin D Deficiency 48 months | 2028-06-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07581184 is a Phase 1, recruiting study with not reported planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “Occurrence of adverse events by severity and occurrence of serious adverse events (SAEs) in participants who received [225Ac]Ac-AKY-2519” over “Up to 30 days following last administration of [225Ac]Ac-AKY-2519.” The retrieved endpoint description is: An AE is defined as any untoward medical occurrence in a participant administered study drug, which does not necessarily have to have a causal relationship with the study drug. The number of patients experiencing an AE and the number of patients experiencing an SAE will be reported. Up to 30 days following last administration of \[225Ac\]Ac-AKY-2519.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
0 recent result records were selected as contextual evidence for Metastatic castration-resistant prostate cancer. These records do not establish direct evidence for NCT07581184 unless the registration number matches.
Indexed evidence status
No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
[64Cu]Cu-AKY-2519 is indexed as Diagnostic radiopharmaceuticals with CD276 biology and a global stage of IND Approval. The asset profile lists Aktis Oncology, Inc. as an originator or developer.
Aktis Oncology, Inc. is indexed in an unreported country with the website http://www.aktisoncology.com. Aktis Oncology is a biotechnology company that designs and develops novel class radiopharmaceuticals. The record lists 5 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether [64Cu]Cu-AKY-2519 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07581184
Protocol source: https://clinicaltrials.gov/study/NCT07581184
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 15 October 2026.
[64Cu]Cu-AKY-2519 in Metastatic castration-resistant prostate cancer is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Occurrence of adverse events by severity and occurrence of serious adverse events (SAEs) in participants who received [225Ac]Ac-AKY-2519 and 2027-12-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
